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INTRODUCTION
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one; Radicut ® ) ( Fig. 1 ) is a unique drug used clinically to treat acute ischemic stroke. Its effect is thought to be based on free radical scavenging from both in vitro and in vivo experimental evidence. [1] [2] [3] [4] [5] [6] [7] [8] [9] For example, it inhibits the oxidation of linoleic acid and salicylate caused by hydroxyl radicals, 1,2 4) and also iron-dependent peroxidation in rat brain and mitochondrial homogenates. 1) From in vitro experiments, edaravone scavenged various free radicals such as hydroxyl radical, peroxyl radical, and DPPH radical. 1, 10, 11) It has three tautomeric forms and an anionic form, as shown in Fig. 1 . It was reported that the anionic form is more reactive than the non-ionic form and that the major reaction products with free radicals such as peroxyl radical and hydroxyl radical are 3-methyl-1-phenyl-2-pyrazolin-2,5-dione and 2-oxo-3-(phenylhydrazono)-butanoic acid 10, 11) . Edaravone prevents lipid peroxidation as efficiently as ascorbic acid and α-tocopherol.
11)
The initial process of radiation damage in the living body is the formation of free radicals. Therefore, radical scavengers and antioxidants, besides antioxidative enzymes, are potential radioprotectors. 12, 13) Indeed, various compounds such as nitroxyls, [14] [15] [16] flavonoids, 17) SOD, 18) and sulfhydryl-containing compounds, 13, 19, 20) having free radical scavenging activity, are reportedly radioprotective. Since edaravone also has free radical-scavenging activity, it is expected to be effective in protecting against the lethal damage caused by ionizing radiation. In the present study, we examined in vivo radioprotection by edaravone against the whole-body X-ray irradiation by using mice.
MATERIALS AND METHODS

Animals
Male C3H mice were obtained from Japan Charles River Laboratories (Yokohama, Japan). The mice, received at 8 weeks of age, were housed five per cage and allowed free access to a commercial diet (Funabashi Farm Co., Funabashi, Japan) and acidified water. The animal rooms were maintained on a 12 h light-dark cycle at an air temperature of 23 ± 1°C and a humidity of 55 ± 5%. The mice were 65-75 days old at the time of irradiation and weighed 24-29 g. The research was conducted with the approval of the institution's animal use committee.
Chemicals
Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). It was dissolved in a small amount of 1 M NaOH solution, the pH was adjusted to 8.8 with HCl, and the concentration was adjusted to 30 mg/ml in the saline solution (Otsuka Pharmaceutical Company, Ltd.).
Irradiation
Each mouse was weighed before the administration of edaravone, which was given to the mice intraperitoneally at a dose of 450 mg/kg body weight (bw) (approximate volume, 0.4 ml). A 0.4 ml volume of saline was injected i.p. into the control mice. A group of 10 mice were transferred to a round Lucite container (12 rooms, 23 cm in diameter, 4 cm heigh). The container was placed on the stand of an irradiator (Pantak HF-320, Shimadzu, Kyoto, Japan), and the mice were irradiated at various whole-body doses with X-rays at 200 kV and 20 mA with a filter (0.5 mm Cu/0.5 mm Al). The radiation dose was determined with a dose meter placed in a compartment of the container. The dose rate used was about 0.55 Gy/ min. Throughout most of our experiment, the radiation dose was set at 8.0 Gy. Immediately after irradiation, the mice were separated into groups of 5 and assessed daily for survival for 30 days.
Measurement of heart rate, blood pressure, and body temperature
We measured the heart rate and blood pressure of the mice by an improved noninvasive tail-cuff method that required no preheating, using a BP monitor for Rats & Mice Model MK-2000 (Muromachi Kikai, Tokyo, Japan). The heart rate was determined by converting the time in which 20 pulses are recorded. For the blood pressure, systolic pressure was measured. The systolic blood pressure is defined empirically as the point when the pulse reappears. The body temperature was measured at the rectum of the mice with a digital thermometer (TD-300, Shibaura Electronics Co. Ltd.).
Statistical analysis
We analyzed the experimental data statistically with computer software, StatView (SAS Institute Inc., Cary, NC). The non-parametric Logrank test was used to test the survival curve (Kaplan-Meier curve). The Student's t-test (unpaired) was also used to test the mean surviving period.
RESULTS
To assess the radioprotective activity of edaravone, the compound was injected i.p. in various doses at various times either before or after the whole-body X-ray irradiation. Figure  2 shows the effect of the timing of edaravone administration on the survival curve and mean surviving period. It was injected i.p. at a dose of 450 mg/kg bw at various time points prior to or immediately after the 8 Gy irradiation. The mean surviving period is defined as the average number of days alive with a cut-off at 30 days. Therefore the maximum value for 100% survival is 30 days. As clearly shown in Fig. 2 , edaravone administered at 15, 30, or 45 min prior to the irradiation showed significant radiation protection compared to the control (p < 0.001). An administration 30 min prior to the irradiation gives the best result. Treatment 60 min prior to the irradiation or post-irradiation showed no significant effect. Based on this finding, we set the timing of the administration of edaravone at 30 min prior to the irradiation. Figure 3 shows the effect of an injection dose of edaravone on the survival of mice. Survival increased with the injection dose and reached a plateau at 450 mg/kg bw. Doses higher than 450 mg/kg had no further effect. Figure 4 shows the effect of the total radiation dose on survival to obtain LD50/30. The dose of edaravone was 450 mg/kg bw, and the timing of the administration was 30 min prior to the irradiation. For the control, a saline solution (0.3 ml/ mouse) was injected i.p. prior to the irradiation. The LD50/30 was about 8.8 Gy for edaravone-injected mice and 6.6 Gy for control mice, yielding a DRF for edaravone (450 mg/kg bw) of 1.3.
The effect of edaravone on the physiological parameters of mice was measured after i.p. injection. No significant effect was observed on heart rate or blood pressure at the dose of 450 mg/kg bw (data not shown). On the other hand, body temperature decreased significantly, reached a minimum (3-6°C and about 3°C lower for 450 mg/kg bw and 300 mg/kg bw, respectively, with respect to the normal temperature) at 30 to 60 min post-injection, then slowly recovered (Fig. 5) . 
DISCUSSION
In the present study, we demonstrated that edaravone, used clinically to treat stroke, was effective as a radioprotective agent in mice with respect to 30-day survival after a lethal dose (8 Gy) of X-ray irradiation. The radiation dose of 8.0 Gy is within the range causing bone-marrow syndrome, and the death is a result of radiation damage to the hematopoietic system in mice. 21, 22) Although we cannot completely exclude the gastro-intestinal syndrome, which is said to occur at about 10-100 Gy, 21, 22) the contribution of the gastro-intestinal injuries to death caused by the irradiation of 8.0 Gy observed after 3 . Effect of dose of edaravone on the survival of mice exposed to whole-body X-ray irradiation. Various amounts of edaravone were administered i.p. 30 min prior to whole body X-ray irradiation (8 Gy). For the control, 0.3 ml of saline solution was injected i.p. at 30 min prior to the irradiation. The number of mice is 10 for each condition, and the error bar shows S.E. Statistical significance compared to the control (zero injection dose): **p < 0.001; ***p < 0.0001. Fig. 4 . Effect of radiation dose on the survival of mice after an injection of edaravone (solid circles) or saline (open circles). Edaravone (450 mg/kg bw) or saline (0.3 ml) was administered i.p. 30 min prior to whole-body X-ray irradiation. The y-axis is the probit form of the survival (x%) at different radiation doses. The cross point with the x-axis shows the LD50/30 value: 6.6 Gy for control and 8.8 Gy for edaravone.
2 weeks should be viewed as negligible.
It is important to investigate the mechanism of radioprotection once we find the in vivo effects. Although the present results showed only phenomenological results, the finding that the administration of the drug post-irradiation was ineffective suggests that the drug works by reacting with initial species with a short lifetime arising from the irradiation. Edaravone scavenges various free radicals, 1, 10, 11) and the irradiation generates hydroxyl radical, 23) which is one of the most probable candidates that edaravone scavenges. Peroxyl radicals generated just after the irradiation, which immediately react with biological components, would also be possible candidates, if such radicals are present. Although edaravone is a very effective agent to protect lipid peroxidation, the slow process of the propagation of lipid peroxidation could not be the cause of death by the irradiation because an administration of edaravone immediately after the irradiation had no effect.
The protective effect was observed beginning at a dose of 300 mg/kg bw administrated i.p. and reached a maximum at 450 mg/kg bw. A higher dose, 600 mg/kg bw, had a similar effect to 450 mg/kg bw. This dose range has the same order of magnitude as that observed for other radioprotectors with a low molecular weight, such as lipoic acid and tempol. 13, 14) However, the dose range is about 2 orders of magnitude larger than the dose used clinically (3 mg/kg bw, i.v.) to protect the human brain from acute ischemic stroke. Besides the dose range, the administration route also differed from that used clinically: i.p. in this study and i.v. for clinical use.
Radioprotection by chemical agents is usually dependent on the timing of the administration. It was reported that tempol showed radioprotection when administered 5-10 min prior to irradiation, but not if administered 24 h prior. 14) We investigated the time frame for the effect of edaravone in this study and found that it is best administered 30 min prior to the irradiation. Since radioprotection was observed only when edaravone was administered before irradiation, the primary action of edaravone might be the quenching of free radicals generated by the irradiation. Its concentration in the plasma of the mice was highest at 5 min after i.p administration and decreased with time (data not shown). Therefore the effect observed following an administration 30 min prior to the irradiation suggests that drug delivery to target tissues from the blood and/or some metabolism within the cells may be responsible for this time frame.
As shown in Fig. 4 , the LD50/30 of control mice was estimated as 6.6 Gy. This value is consistent with the value reported for mice (6.4 Gy). 21) When edaravone (450 mg/kg bw) was administered 30 min prior to the irradiation, the LD50/30 value increased to about 8.8 Gy. The dose reduction factor (DRF) value is calculated to be about 1.3. This value is similar to the value for tempol, an antioxidant radioprotector. 14) Edaravone at 450 mg/kg bw lowered the body temperature of the mice by 3-6°C. In general, lowering the body temperature decreases the metabolism of the body, which may reduce the damage caused by irradiation. Furthermore, there is a report showing radioprotection by lowering the body temperature. 24) However, two different doses (450 and 300 mg/kg bw) showed significantly different radioprotective effects (Fig. 3) in spite of the similar kinetics of body temperature in individual mice, which is all kept low during about 20-100 min after the drug administration either with 300 mg/kg bw or 450 mg/kg bw (Fig. 5) . Therefore, even if the effect of lowering body temperature influenced the radioprotection, the contribution would be very small. 5 . Body temperature of mice after an administration of edaravone. Edaravone (A:450 mg/kg bw and B:300 mg/kg bw) was injected i.p., and the body temperature of mice was measured at the rectum with a digital thermometer (TD-300, Shibaura Electronics Co. Ltd.). Individual data for 8 mice for A and 5 mice for B are shown.
In the present study, we have shown that edaravone is an effective radioprotector against lethal whole body X-ray irradiation in mice. Since it is already in clinical use, it is a potential radioprotector for humans.
